Poseltinib

Poseltinib (HM71224, LY3337641) is an experimental Bruton's tyrosine kinase inhibitor for the treatment of rheumatoid arthritis. It was developed by Hanmi Pharmaceutical and licensed to Eli Lilly.[1]

Poseltinib
Clinical data
Other namesHM-7122; LY 3337641
Identifiers
  • N-(3-((2-((4-(4-Methylpiperazin-1-yl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC26H26N6O3
Molar mass470.533 g·mol−1
3D model (JSmol)
  • C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1
  • InChI=1S/C26H26N6O3/c1-3-23(33)27-19-5-4-6-21(17-19)35-25-24-22(11-16-34-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)
  • Key:LZMJNVRJMFMYQS-UHFFFAOYSA-N

Phase II clinical trials began in August 2016 in patients with rheumatoid arthritis. Additional phase II trials are planned for treatment of lupus, lupus nephritis, Sjögren's syndrome, and other immunological conditions.[2]

References
  1. Alternative Names: HM 71224; LY 3337641. "Poseltinib - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.{{cite web}}: CS1 maint: multiple names: authors list (link)
  2. "Lilly and Hanmi Announce an Exclusive License and Collaboration Agreement for the Development and Commercialization of an Immunological Therapy (NYSE:LLY)". Investor.lilly.com. 2015-03-19. Retrieved 2017-05-22.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.